Friend virus induces massive splenomegaly and erythroblastosis in susceptible mice (1, 2). Certain strains of Friend virus, designated FV-P 1 for polycythemia (3), cause the rapid accumulation of erythroid precursors that can differentiate in vivo (4, 5) and in vitro (6, 7) in the absence of erythropoietin. Mice infected with these strains of Friend virus experience a tremendous increase in the rate of erythropoiesis (8) and become polycythemic. The component of Friend virus stocks that is thought to be responsible for inducing polycythemia is a replication-defective virus called spleen focus-forming virus (SFFV; 9-11). Understanding the mechanism of FV-P-stimulated, erythropoietin-independent erythropoiesis should provide fundamental insights into erythroid differentiation and viral leukemogenesis.
Friend virus induces massive splenomegaly and erythroblastosis in susceptible mice (1, 2). Certain strains of Friend virus, designated FV-P 1 for polycythemia (3) , cause the rapid accumulation of erythroid precursors that can differentiate in vivo (4, 5) and in vitro (6, 7) in the absence of erythropoietin. Mice infected with these strains of Friend virus experience a tremendous increase in the rate of erythropoiesis (8) and become polycythemic. The component of Friend virus stocks that is thought to be responsible for inducing polycythemia is a replication-defective virus called spleen focus-forming virus (SFFV; [9] [10] [11] . Understanding the mechanism of FV-P-stimulated, erythropoietin-independent erythropoiesis should provide fundamental insights into erythroid differentiation and viral leukemogenesis.
Mouse strains that carry the Fv-2 r allele (12) are strongly resistant to Friend virusstimulated erythropoiesis (13, 14) . The mechanism of this resistance is not well understood. On the one hand, Fv-2 controls the replication of SFFV in vivo (13) and in long-term bone marrow cultures (15) , although not in fibroblasts (16) . Restricted replication of SFFV in Fv-2 ~ mice could explain their relative resistance to virusstimulated erythropoiesis. On the other hand, the Fv-2 gene also plays a role in normal erythropoiesis, controlling the proportion of early erythroid precursors synthesizing DNA (17) , and regulating the expression of virus-related RNA (18) and a virusrelated differentiation antigen in uninfected hemopoietic cells (19) . These pleiotropic effects of Fv-2 on normal erythropoiesis could also be related to the mechanism of resistance to virus-stimulated erythropoiesis. The experiments reported here were designed to investigate whether Fv-2 ~ restriction of SFFV replication, or some other effect of the Fv-2 ~ gene, is responsible for resistance of Fv-2 ~ mice to Friend virusstimulated erythropoiesis.
In these experiments, bone marrow chimeras containing mixtures of Fv-2 ~ and Fv-288 bone marrow were constructed. The bone marrow donors were chosen to differ in hemoglobin type so that the proportion oferythrocytes derived from each donor in the chimera could be determined by hemoglobin electrophoresis. These chimeric mice were infected with FV-P, and the effect of the virus on erythropoiesis derived from each donor marrow was determined at various times after infection.
Previous experiments have shown that Fv-2 phenotype is determined by the transplanted bone marrow cells in radiation chimeras. Thus, transplantation of bone marrow into lethally irradiated Fv-2 '~ mice renders them susceptible to Friend virus, whereas transplantation of Fv-2 rr bone marrow into Fv-2 ss mice renders them resistant (14, 20) . Radiation chimeras containing mixtures of F v-2 ~ and Fv-2 ~ bone marrow are susceptible to Friend virus as determined by spleen focus formation (14) , as are F1 mice of Fv-2 '~ × Fv-2 ~ crosses. Because spleen foci are associated with proliferating ~:ells of the erythroid lineage (9) , it seemed likely that chimeras containing mixtures of Fv-2 '~ and Fv-2 ~ bone marrow would be susceptible to virus-stimulated erythropoiesis.
The experimental results show that chimeras containing mixtures of Fv-2 ~ and Fv-2 s` bone marrow are indeed susceptible to virus-stimulated erythropoiesis, but that the Fv-2 '~ bone marrow maintains its resistance in the chimeras. Because both bone marrows are exposed to the same amount of SFFV in these mice, the results indicate that Fv-2 ~ bone marrow is resistant to virus-stimulated erythropoiesis even when exposed to an amount of SFFV sufficient to stimulate Fv-2 ~ erythroid precursors. This implies that Fv-2 ~r mice are resistant to virus-stimulated erythropoiesis for reasons other than poor replication of SFFV.
Materials and Methods
Mice. DBA/2, B10.D2, and (C57BL/10 × DBA/2)FI (BDF1) mice were obtained from the Imperial Cancer Research Fund Laboratories.
Virus. NB-tropic (21) FV-P was a gift from F. Lilly (Department of Genetics, Albert Einstein College of Medicine) and was routinely passaged as a 10% spleen homogenate in DBA/2 or BDFx mice. This virus gave approximately equal spleen focus-forming titers (9) in DBA/2 and BDF1 mice.
Radiation Chimeras. 3-5-mo-old male DBA/2 or female B10.D2 mice were exposed to 1,000 :1:50 rad (240 kV, 14.5 mA, 130 rad/min, 18" from x-ray source to target). Immediately after irradiation, mice were transfused through the tail vein with 7 × 10 e bone marrow cells from DBA/2 donors, B10.D2 donors, or mixtures of bone marrow cells from the two donors. Irradiated controls that were not transfused with bone marrow all died within 2 wk. Mice transplanted with viable bone marrow cells had a survival of ~85% at 1 mo with sporadic deaths for 4-6 mo thereafter, at which time the experiments were terminated.
Phenylhydrazine (PHZ) Treatment. Mice were injected with 0.8 mg of PHZ intraperitoneally or subcutaneously at the indicated times after bone marrow transplantation and/or virus infection.
Routine Hematology. Mice were bled from the tail vein. Hematoerits were measured using heparinized microhematocrit tubes. Reticulocytes were stained with 1% brilliant cresyl blue (22) .
Hemoglobin Electrophoresis. Erythrocytes were washed three times with normal saline and lysed in 15 vol of solution containing 67 mM cystamine d~ydrochloride (Aldrich Chemical Co., Inc., Milwaukee, Wis.), 103 mM dithiothreitol, and 0.25% NH3OH (23) . Membranes were removed by centrifugation. Hemolysates were electrophoresed for 2-4 h at 225 V on cellulose acetate strips (Shandon "cellogram" [Shandon Southern Iristruments, Inc., Sewickley, Pa.] or Whatman "celloger' [Whatman, Inc., Clifton, N. J.]) using a buffer containing 180 mM Tris, 100 mM boric acid, and 2 mM EDTA, pH 8.9. Some gels were stained with 1% Ponceau S in 45% methanol-5% acetic acid and destained in 5% acetic acid. Other gels were air dried and autoradiographed using Kodak XR-5 film (Eastman Kodak Co., Rochester, N. Y.).
~gFe Labeling. Intact mice were injected intravenously or intraperitoneally with 1-10/xCi of freshly buffered SgFec13 (2-20 ~Ci//xg; Amersham Corp., Arlington Heights, Ill.) and bled 2 d later. In some experiments, reticulocytes were labeled in vitro by adding 20 #1 of whole blood to a solution containing 0.45 ml dialyzed fetal calf serum, 0.45 ml a medium (Flow Laboratories, Inc., Rockville, Md.), and 0.1 ml (5 #Ci) of freshly buffered 59FeCI3. The mixture was incubated at 37°C for 2-8 h. Radiolabele'd erythrocytes were washed three to six times with Dulbecco's modified Eagle's medium to remove excess label and then prepared for hemoglobin electrophoresis as above. Hemolysates were kept at 4°C and electrophoresed within 12 h.
Quantitation of the Relative Amount of Each Hemoglobin Type. Individual hemoglobin bands were cut from the cellulose acetate strips and eluted in 1 ml of distilled H~O. Absorbance of each eluate was measured spectrophotometrically at 415 nm. The relative amount of each hemoglobin type in a mixture was calculated as the ratio of absorbance of the eluate from that band to the total hemoglobin absorbance (24) . Radioactivity was measured in a Beckman liquid scintillation counter (Beckman Instruments, Inc., Fullerton, Calif.). The relative amount of newly synthesized hemoglobin of each type was calculated as the ratio of dpm in the eluate from a particular hemoglobin band to the total dpm from all hemoglobin bands. Aliquots of 5-60 #1 of hemolysate were used for each sample (applied as a linear streak 5 #l/cm) so that the total number of hemoglobin-associated dpm was about 2,000 per sample.
Statistics. The proportion of total or newly synthesized hemoglobin of a given type was determined for each mouse. These values were averaged for mice within each group. Statistical significance was calculated using the two-tailed Student's t test. amounts of newly synthesized hemoglobin of different types is very simple, but has a potential disadvantage. If there were a significant iron exchange between hemoglobin molecules in a hemolysate (25) , one could not use the proportion of 59Fe in one hemoglobin band to measure its relative synthesis rate. To test whether iron exchange would pose a problem, the following control experiments were done.
In one set of experiments, 59Fe-labeled erythrocytes of each hemoglobin type were mixed with unlabeled erythrocytes of the other hemoglobin type. The mixtures were hemolyzed and electrophoresed after incubation for various times. It was found that hemolysates kept at 4°C and electrophoresed within 12 h showed <10% incorporation of radioactivity into the originally unlabeled hemoglobin type. Longer incubations and higher temperatures resulted in greater transfer of label. Therefore, to minimize iron exchange, hemolysates were kept cold and electrophoresed within 12 h.
A more physiological control experiment is shown in Fig. 2 . D B A / 2 mice were lethally irradiated (1,000 _+ 50 rad) and transfused with 7 × 106 bone marrow cells from D B A / 2 donors, B 10.D2 donors, or a 1:1 mixture of bone marrow cells from the two strains. 1 mo after transplantation, the recipients were injected with 1 #Ci of 59Fe intravenously and bled 2 d later. Because mouse erythrocytes have a life span of about 50 d (26) , at 1 mo after bone marrow transplantation, approximately half of the circulating erythrocytes should be of recipient type, having been formed before the transplant, whereas the remaining erythrocytes should be of donor type, having been synthesized after the transplant. The upper panel of Fig. 2 shows that mice transplanted with B10.D2 bone marrow had ~50% DBA/2-type hemoglobin and 50% B10.D2-type hemoglobin, whereas mice that received a 1:1 mixture of B10.D2 and D B A / 2 bone marrow had ~75% DBA/2-type hemoglobin and 25% B10.D2-type hemoglobin, as expected. The lower panel of shown in the upper panel. It demonstrates clearly that only the donor-type hemoglobin is radioactive, despite the presence of up to 50% unlabeled recipient-type hemoglobin in the sample. This experiment shows that one can selectively label newly synthesized hemoglobin with 59Fe in chimeras containing both types of hemoglobin. Because iron exchange between labeled and unlabeled hemoglobin molecules did not occur to a significant extent, the method was deemed adequate to measure relative rates of synthesis of different hemoglobin types in chimeras infected with FV-P. (27) . A Coombs test was done to investigate the possibility of immune erythrocyte destruction; no Coombs-positive chimeras were found.
Stability of Hemoglobin Type in Radiation

Effect of FV-P on Hemoglobin Synthesis in Radiation Chimeras. Groups of chimeras
containing mixtures of B10.D2 and D B A / 2 bone marrow were infected with 1,000 focus-forming units (FFU) of FV-P and examined for type of hemoglobin being synthesized 1 mo later. As shown in Fig. 3 , infected chimeras stopped synthesizing B10.D2 hemoglobin, whereas control chimeras continued to synthesize both types of hemoglobin. This result was independent of whether the irradiated host was D B A / 2 or BI0.D2.
Quantitative results from this experiment are shown in Table I . In uninfected * Hematocrits on day 17 after infection. :]: P < 0.001 compared with control group. § P < 0.02 compared with control group.
B10.D2 chimeras, 36% of newly synthesized and 38% of total hemoglobin was of B 10.D2 type. Infected chimeras were slightly polycythemic (mean hematocrit ~-54%) and reticuloeytotic (mean reticulocyte count = 12%) 4 wk after infection. At that time, 28% of the total hemoglobin and <10% of the newly synthesized hemoglobin was of B10.D2 type. The fall in the proportion of B10.D2 hemoglobin in infected animals is consistent with decreased synthesis of B10.D2 hemoglobin in the weeks after infection. Similar results are shown for the DBA/2 chimeras. As noted above, some uninfected chimeras followed from 2 to 4 mo after transplantation also showed a decrease in the proportion of B10.D2 hemoglobin. This raised the possibility that Friend virus might simply accelerate a normal shift to DBA/2 hemoglobin in the chimeras, perhaps by increasing the rate of erythropoiesis or shortening erythrocyte survival nonspecifically (28) . To test whether other agents that shorten erythrocyte survival and stimulate erythropoiesis would accelerate a shift toward DBA/2 hemoglobin, groups of chimeras were given repeated injections of PHZ. PHZ causes acute hemolysis with a compensatory increase in the rate of erythropoiesis. The dose and schedule of PHZ administration were chosen to produce at least as much stimulation of erythropoiesis, as estimated by reticulocyte count, as seen in Friend virus-infected chimeras. Tables II and III show that PHZ does not significantly alter the proportional rate of B10.D2 hemoglobin synthesis in the chimeras (compare groups I and II), whereas Friend virus dramatically reduces it (groups III and IV). We conclude that the effect of Friend virus infection is not the result of a general increase in the rate of erythrocytes synthesis or destruction.
The results so far are consistent with B 10.D2 bone marrow remaining resistant to Friend virus-stimulated, erythropoietin-independent erythropoiesis in the chimeras. In such infected polycythemic chimeras, erythropoietin would be expected to be suppressed (4, 5) , and in the absence of erythropoietin, B10.D2 erythroid precursors might not be induced to differentiate. To test whether B10.D2 erythroid precursors remained subject to normal erythropoietic stimulation in the infected chimeras, groups of infected animals were given PHZ after they had become polycythemic. As B10.D2 mice were lethally irradiated and transplanted with a h l mixture of DBA/2 and B10.D2 bone marrow cells 2 mo before the start of the experiment. Hemoglobin was labeled in vivo by injecting 10 #Ci ~Fe intravenously 2 d before the final bleeding. Group I, control chimeras; group II, chimeras injected with 0.8 mg PHZ intraperitoneally on days 0, 4, 9, 12, 20, and 21, and bled on day 25; group III, chimeras infected with 100 FFU of FV-P on day 0 and bled on day 25; group IV, same as group III, but infected with 1,000 FFU of FV-P; group V, two chimeras infected with 100 FFU and one chimera infected with 1,000 FFU of FV-P on day 0. These mice were bled on day 22 (before PHZ) and then given 0.8 mg PHZ subcutaneously on days 22 and 23 and bled again on day 28 (after PHZ). Numbers in the table represent the mean ± SD. * P < 0.05 compared with controls. P < 0.001 compared with controls. § P < 0.05 compared with group III. DBA/2 mice were lethally irradiated and transplanted with a h l mixture of DBA/2 and B10.D2 bone marrow cells 2.5 mo before the start of the experiment. At the indicated times after infection (day 0) or after the start of PHZ administration (day 0), chimeras were bled (100 #1 from the tail vein) and reticulocytes were labeled in vitro with ~Fe. Group I, control chimeras; group II, chimeras given PHZ (0.8 mg) intraperitoneally on days 0, 1, 6, and 11; group III, eight chimeras infected with 1,000 FFU of FV-P on day 0; group IV, two mice from group III and two additional chimeras infected with 1,000 FFU of FV-P on day 0; group V, six mice from group III given PHZ (0.8 mg) subcutaneously on days 18, 19, and 20. Numbers in the table are mean ± SD. * P < 0.00l compared with control group. :~ P < 0.001 compared with group IV.
shown in Tables II and III (group V) , PHZ treatment of infected plethoric chimeras reduced the hematocrit and restored synthesis of B 10.D2 hemoglobin.
In most uninfected chimeras, the proportion of newly synthesized hemoglobin of B10.D2 type is slightly less than the proportion of total hemoglobin of B 10.D2 type (Tables I-III) . The difference between these proportions was calculated for each chimera. When the data from all chimeras were combined, the average difference was 6.3 ± 1.4% (mean +_ SEM). This number is significantly different from zero (P < 0.001). The fact that the proportion of total hemoglobin of B10.D2 type is slightly, but significantly, greater than the proportion of newly synthesized hemoglobin of B10.D2 type, suggests a gradual decrease in the relative rate of synthesis of B10.D2 hemoglobin. Such a decrease is consistent with the observation of a gradual fall in the proportion of B10.D2 hemoglobin in uninfected chimeras followed for 2-4 mo after transplantation (see above).
In animals treated with PHZ, there is closer agreement between the proportion of newly synthesized hemoglobin of B 10.D2 type and the proportion of total hemoglobin of B10.D2 type (Tables II and III) . The difference between these proportions was calculated for each chimera treated with PHZ. The average difference was found to be 1.0 ± 1.3% (mean ± SEM), not significantly different from zero (P > 0.4). This result is not surprising because PHZ causes massive hemolysis, destroying old erythrocytes; after PHZ treatment, nearly all of the hemoglobin present is newly synthesized. Hence, the proportion of total hemoglobin of B10.D2 type should be the same as the proportion of newly synthesized hemoglobin of B 10.D2 type.
It is possible that PHZ treatment could artifactually produce close agreement between the proportion of total and newly synthesized hemoglobin of B10.D2 type. This would be the case if PHZ increased the rate of iron exchange between hemoglobin molecules (for example, by increasing the amount of methemoglobin, a species that facilitates iron exchange) (25, 29) . However, this possibility is extremely unlikely because (a) PHZ treatment was always stopped several days before 59Fe labeling and preparation of hemolysates, (b) no increase in methemoglobin was detected (<1%) in blood samples from mice treated 2 d earlier with PHZ, and (c) no increase in iron exchange between labeled and unlabeled hemoglobins was observed when these hemoglobins were obtained from mice treated with PHZ (data not shown).
Discussion
The experiments reported here show that B10.D2 bone marrow remains resistant to Friend virus-stimulated erythropoiesis even when exposed to an amount of SFFV that, in the same chimeric animal, stimulates DBA/2 erythroid precursors. One may conclude that resistance to virus-stimulated erythropoiesis is an intrinsic property of B 10.D2 erythroid precursors. This, in turn, implies that B 10.D2 mice are resistant to Friend virus-stimulated erythropoiesis for reasons other than poor replication of SFFV.
The experimental results strongly suggest that DBA/2 erythroid precursors become independent of erythropoietin in the infected chimeras, because DBA/2 hemoglobin synthesis continues after the mice have become polycythemic. Previous experiments have shown that erythropoietin, the physiological regulator of erythropoiesis, is undetectable in polycythemic Friend virus-infected mice (4, 5) . Our experiments suggest that B 10.D2 erythroid precursors remain under erythropoietin control because B10.D2 hemoglobin synthesis stops when infected chimeras become polycythemic, and starts again when the mice are made anemic with PHZ. However, the erythropoietin dependence of B 10.D2 erythroid precursors must remain conjectural because erythropoietin levels were not measured, and PHZ may stimulate erythropoesis by mechanisms other than simply the release of erythropoietin.
The relationship between SFFV replication and virus-stimulated erythropoiesis may be quite complex on a cellular level. For example, it is possible that SFFV must infect erythroid precursors to induce them to differentiate in the absence of erythropoietin. According to this hypothesis, if the Fv-2 r gene prevented SFFV from replicating in hemopoietic cells (15) , it could block virus-stimulated erythropoiesis. On the other hand, it has also been suggested that the majority of SFFV produced in vivo may come from rapidly proliferating hemopoietic cells (16) . By this hypothesis, if the primary effect of the Fv-2 ~ gene were to block virus-stimulated erythropoiesis, then poor SFFV replication in the animal would follow secondarily. To investigate these hypotheses, it will be important to determine whether B10.D2 hemopoietic cells in the chimeras are themselves infected with SFFV.
The experimental results provide additional evidence that virus-stimulated erythropoiesis is not mediated by erythropoietin, other humoral factors or cell-cell interactions that substitute for erythropoietin. If such mechanisms were involved in virusstimulated erythropoiesis, they would be expected to act "in trans" on B10.D2 erythroid precursors in the chimeras, leading to apparent loss of resistance of B 10.D2 bone marrow. This was not observed. Of course, the experiments do not rule out the possibility of erythropoietic factors or cell-cell interactions that do not operate across strain barriers, or whose action might be modified by SFFV infection of erythroid precursors.
The experimental results raise may questions about the nature and level of the block to B 10.D2 hemoglobin synthesis in the infected chimeras. Is terminal differentiation of B10.D2 erythroid precursors blocked merely by the absence of erythropoietin, or do suppressive factors or interactions exist, as have been suggested for inhibition of normal stem cells in patients with polycythemia vera (30)? Are B10.D2 erythroid precursors increased in number of the bone marrow and/or spleens of infected chimeras? The latter might be suspected because DBA/2 erythroid precursors should be increased in number in the infected chimeras (31) , and yet a large fraction of newly synthesized hemoglobin is of B10.D2 type after treatment with PHZ. The application of clonal assays of erythroid precursors to this system should help answer these questions.
Because these experiments were done with strains of mice that differ at many loci, one cannot with assurance attribute the observed effects to particular genes such as Fv-2. Thus, although it might be tempting to relate the slow increase in DBA/2 hemoglobin in uninfected chimeras to Fv-2-controlled differences in rate of cycling of erythroid precursors (17) , one cannot rule out effects due, for example, to minor histocompatibility differences. Similarly, the resistance of B10.D2 bone marrow to Friend virus-stimulated erythropoiesis in the chimeras could be due to other Friend virus resistance genes in the B10 strain background (32, 33) . Experiments using congenic strains differing only at Fv-2 and Hbb should clarify these points.
Although the chimeras used in these experiments were susceptible to Friend virusstimulated erythropoiesis, they were clearly less susceptible than nonirradiated DBA/2 controls. This was apparent in the low levels of polycythemia achieved after a substantial dose of SFFV, a reduced degree ofsplenomegaly in the infected chimeras, and a delay in death from leukemia among chimeras compared with DBA/2 controls (unpublished observations). The relative resistance of the chimeras to Friend virus could have been contributed by the B10.D2 bone marrow, because the B10 background carries genes that affect the immune response to Friend virus (32, 33).
The experimental system described here is analogous to a rare "experiment of nature": glucose 6-phosphate dehydrogenase (G6PD) heterozygous women with polycythemia vera. Elegant studies of two such women, who are "natural" chimeras for the X chromosome-coded enzyme G6PD, show that erythropoietin-independent erythroid precursors are all of one G6PD type, whereas some erythropoietin-dependent erythroid precursors carry the other G6PD type (30) . These studies support the hypothesis that polycythemia vera is a clonal disease and provide a way to study the interaction between the "polycythemia" clone and "normal" stem cells in a single host. In the artificial murine chimeras described here, erythropoietin-independent erythroid precursors carry one hemoglobin type, whereas seemingly erythropoietindependent erythroid precursors carry the other hemoglobin type. It should therefore be possible to do similar studies to investigate the interaction between "normal" and "diseased" erythroid precursors in these Friend virus-infected bone marrow chimeras. The animal system has obvious advantages in terms of reproducibility and manipulability compared with the rare human condition for which it serves as a model.
Summary
Bone marrow chimeras were formed containing mixtures of DBA/2 (Fv-288, Hbb dd) and B10.D2 (Fv-2 ~, Hbb ~) bone marrow. When these mice were infected with the polycythemia-inducing strain of Friend virus, erythropoiesis was stimulated, but the proportion of B 10.D2 hemoglobin fell rapidly and newly synthesized hemoglobin was essentially all of the DBA/2 type. The treatment of infected polycythemic chimeras with phenylhydrazine lowered the hematocrit and restored the synthesis of B10.D2 hemoglobin. These results imply that B10.D2 erythroid precursors are intrinsically resistant to Friend virus-stimulated erythropoiesis. The experiments also suggest that virus-stimulated erythropoiesis is not mediated by a factor or cell-cell interactions, unless such factors or interactions do not act across strain barriers.
